Swiss Medtech giant Ypsomed expands to US with $220M facility in North Carolina
Subscribe to our free newsletter today to keep up to date with the latest manufacturing news.
Swiss medtech company Ypsomed is making its first major move into the US market with a $220 million manufacturing facility in Holly Springs, North Carolina. The site, set to begin operations by 2027, will produce injection systems for self-medication and marks a significant step in the company’s global expansion strategy. By choosing the Research Triangle region, Ypsomed aims to align itself with the pharmaceutical and biotechnology firms it already serves in North America.
With an initial workforce of 100 and plans to grow to 200 based on market demand, the new plant will give Ypsomed a domestic production base for its high-demand drug delivery systems. The company says the location strengthens both its ability to serve customers and its overall supply chain resilience. CEO Simon Michel described the move as a deliberate decision to bring operations closer to major clients and ensure continuity of supply across key markets.
Why Holly Springs was the choice
North Carolina has emerged as a hotspot for medtech expansion in recent years. Ypsomed’s decision to settle in Holly Springs is rooted in access to the region’s 650-plus life sciences companies, top-tier research universities and a talent pool built for the industry. The Research Triangle, anchored by Duke University, UNC Chapel Hill and NC State University, is among the most concentrated life sciences clusters in the country.
The company is acquiring a 15,000-square-meter industrial building with room for future expansion. For a firm rooted in Swiss manufacturing precision, the site offers a ready-made foundation to build out a modern production hub. Local and state officials have emphasized their support, seeing Ypsomed’s presence as a boost to North Carolina’s position as a center for high-value medical device manufacturing.
Global network, local impact
Ypsomed’s US move is part of a wider global strategy that includes new operations in China and Germany, along with expansion at its headquarters site in Solothurn, Switzerland. The company is responding to increasing demand for self-medication technology, driven by the growth of biologics, the shift to at-home care and greater patient autonomy in managing chronic conditions.
In Germany, its “Schwerin 2” plant is introducing next-generation technologies designed to improve efficiency and flexibility across production lines. Meanwhile, the new facility in Changzhou, China, gives the company a stronger foothold in the Asia-Pacific region. The addition of a US site completes a tri-continental manufacturing footprint aimed at providing local solutions in three of the largest healthcare markets in the world.
Demand for self-medication technology on the rise
As injectable therapies become more prevalent across therapeutic areas such as diabetes, oncology and autoimmune disorders, the demand for advanced self-injection systems continues to grow. Ypsomed’s portfolio includes auto-injectors, pens and infusion systems tailored to pharmaceutical and biotech companies that are developing next-generation therapies.
The Holly Springs facility is set to help meet this rising demand by delivering precision-engineered drug delivery systems to customers in the US. With medtech companies under pressure to shorten time-to-market while meeting regulatory and quality requirements, proximity to manufacturing has become a competitive advantage. For Ypsomed, this investment is both a strategic commitment to the US healthcare market and a response to evolving patient expectations around accessibility, usability and autonomy in care delivery.
Sources: